Patent application number | Description | Published |
20090281711 | ENERGY-EFFICIENT AUTOMOBILE - Disclosed is an automobile equipped with an engine having an electronically-controlled throttle valve adapted to have an opening angle which is controlled according to an accelerator-pedal depression amount. The engine further includes an accelerator pedal sensor, an actuator adapted to selectively open and close the throttle valve, and a controller. The controller is adapted to calculate a target throttle opening angle corresponding to the accelerator-pedal depression amount, and output a continuous control signal corresponding to the target throttle opening angle, to the actuator. The controller is operable, in a traveling environment of the automobile or an operating condition of the engine where a required engine power is less than an engine power corresponding to the target throttle opening angle, to convert the continuous control signal into a pulsed control signal, and output the pulsed control signal to the actuator. | 11-12-2009 |
20100204332 | METHOD FOR TREATING A DISEASE OR CONDITION RESPONSIVE TO OPENING OF C1C-2 CHANNEL - Disclosed is a method for prophylactic or therapeutic treatment of a condition or disease responsive to opening of ClC-2 channel, which comprises the step of administrating an effective amount of a ClC-2 channel opener to a subject in need of said treatment. According to the invention, a tissue or organ to be transplanted can also be treated with the ClC-2 channel opener. | 08-12-2010 |
20100204489 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE - Disclosed is a method for preparing a prostaglandin derivative of formula (A): | 08-12-2010 |
20100204491 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE - Disclosed is a method for preparing a prostaglandin derivative of formula (A): | 08-12-2010 |
20100267832 | METHOD FOR TREATING MACULAR DEGENERATION - Disclosed is a method for treating macular degeneration in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F | 10-21-2010 |
20100274032 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE - Disclosed is a method for preparing a prostaglandin derivative of formula (A): | 10-28-2010 |
20100298424 | METHOD FOR TREATING ABDOMINAL DISCOMFORT - Disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of abdominal discomfort. Further disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of functional gastrointestinal disorders. | 11-25-2010 |
20110065784 | METHOD FOR PROMOTING GASTROINTESTINAL BICARBONATE SECRETION - Provided is a method for promoting gastrointestinal bicarbonate secretion in a mammalian subject, which comprises administering an effective amount of a compound of Formula (I): | 03-17-2011 |
20110186368 | ELECTRIC VEHICLE AND ELECTRIC SUPPLY ARRANGEMENT FOR THE SAME - In an electric vehicle, a power unit is installed in an internal space region of a tire of each of front and rear wheels. The unit has a plurality of power elements arranged on an inner peripheral surface of a ground contact portion of the tire. Each of the elements includes a core made of a permalloy, and a power coil wound around the core. When a periodically-changing magnetic field is generated in a region above a road by an electric supply arrangement installed in the road, each of the elements generates electric power. This electric power is supplied to a motor of the vehicle through a power distribution system. The motor drives front wheels. The electric vehicle can continuously run over long distances without charging a battery at a buttery station. | 08-04-2011 |
20110244036 | PHARMACEUTICAL COMPOSITION COMPRISING A BI-CYCLIC COMPOUND AND METHOD FOR STABILIZING THE BI-CYCLIC COMPOUND - Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (I): | 10-06-2011 |
20110244037 | PHARMACEUTICAL COMPOSITION COMPRISING A BI-CYCLIC COMPOUND AND METHOD FOR STABILIZING THE BI-CYCLIC COMPOUND - Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (I): | 10-06-2011 |
20110300211 | SOFT-GELATIN CAPSULE FORMULATION - The present invention provides a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which includes: a soft gelatin capsule shell including gelatin and sugar alcohol as a plasticizer, and a mixture including a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved. | 12-08-2011 |
20120022152 | ANTI-CONSTIPATION COMPOSITION - An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): | 01-26-2012 |
20120088823 | COMPOSITION AND METHOD FOR SCALP AND HAIR TREATMENT - Provided is a composition for scalp and hair treatment, comprising a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness. | 04-12-2012 |
20120088824 | DOSAGE UNIT COMPRISING A PROSTAGLANDIN ANALOG FOR TREATING CONSTIPATION - A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. | 04-12-2012 |
20120095090 | NOVEL COMPOSITION AND METHOD FOR STABILIZING THE SAME - Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride. | 04-19-2012 |
20120225938 | METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS - The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound. | 09-06-2012 |
20120237598 | ANTI-CONSTIPATION COMPOSITION - An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): | 09-20-2012 |
20120263803 | AQUEOUS OPHTHALMIC COMPOSITION - Disclosed is an aqueous ophthalmic composition comprising (a) a fatty acid derivative such as a prostaglandin derivative, (b) a polyoxyethylene sorbitan fatty acid ester, (c) an edetic acid compound, (d) a boric acid and a salt of a boric acid, (e) a pharmaceutically acceptable aqueous carrier, and (f) no more than 0.005 w/v % of benzalkonium chloride. The composition is stable and has good anti-microbial properties. | 10-18-2012 |
20130005995 | METHOD FOR PREPARING A FATTY ACID DERIVATIVE - A method for manufacturing a fatty acid derivative represented by formula (I) is provided: | 01-03-2013 |
20130035393 | METHOD FOR TREATING SCHIZOPHRENIA - The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative. | 02-07-2013 |
20130078303 | SOFT-GELATIN CAPSULE FORMULATION - The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved. | 03-28-2013 |
20130143958 | DOSAGE UNIT COMPRISING A PROSTAGLANDIN ANALOG FOR TREATING CONSTIPATION - A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. In particular, the dosage unit includes a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains the PG analog in a range of about 6-96 μg: | 06-06-2013 |
20130217770 | METHOD FOR TREATING IRRITABLE BOWEL SYNDROME BY ADMINISTRATION OF CHLORIDE CHANNEL OPENER - A chloride channel opener, especially a prostaglandin compound, is used for the treatment of functional gastrointestinal disorders. The prostaglandin compound can be, for example, a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E | 08-22-2013 |
20130251744 | VIRUS LIKE PARTICLE COMPOSITION - The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof. | 09-26-2013 |
20130281526 | METHOD FOR TREATING IRRITABLE BOWEL SYNDROME WITH DIARRHEA - A method for treating irritable bowel syndrome with diarrhea in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative is provided. | 10-24-2013 |
20130281637 | FATTY ACID DERIVATIVE-POLYMER CONJUGATE - A fatty acid derivative-polymer conjugate including a conjugate comprising a fatty acid derivative and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided. | 10-24-2013 |
20130281638 | TRICYCLO COMPOUND-POLYMER CONJUGATE - A tricycle compound-polymer conjugate including a conjugate comprising a tricyclo compound and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided. | 10-24-2013 |
20140031428 | METHOD FOR TREATING SCHIZOPHRENIA - The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative. | 01-30-2014 |
20140039058 | OPHTHALMIC SOLUTION - The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient. | 02-06-2014 |
20140066506 | METHOD FOR TREATING MACULAR DEGENERATION - Disclosed is a method for treating macular degeneration in a mammalian subject, which includes administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F | 03-06-2014 |
20140131121 | ELECTRIC VEHICLE AND ELECTRIC SUPPLY ARRANGEMENT FOR THE SAME - In an electric vehicle, a power unit is installed in an internal space region of a tire of each of front and rear wheels. The unit has a plurality of power elements arranged on an inner peripheral surface of a ground contact portion of the tire. Each of the elements includes a core made of a permalloy, and a power coil wound around the core. When a periodically-changing magnetic field is generated in a region above a road by an electric supply arrangement installed in the road, each of the elements generates electric power. This electric power is supplied to a motor of the vehicle through a power distribution system. The motor drives front wheels. The electric vehicle can continuously run over long distances without charging a battery at a buttery station. | 05-15-2014 |
20140171496 | COMPOSITION AND METHOD FOR PROMOTING HAIR GROWTH - The present invention provides a method and composition for promoting hair growth in a mammal which comprises a prostaglandin compound having two hetero atoms at the 15 position as an active ingredient thereof. | 06-19-2014 |
20140194497 | COMPOSITION AND METHOD FOR SCALP AND HAIR TREATMENT - Provided is a composition for scalp and hair treatment, including a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness. | 07-10-2014 |
20140235665 | ANTI-CONSTIPATION COMPOSITION - An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): | 08-21-2014 |
20140287036 | SOFT-GELATIN CAPSULE FORMULATION - The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved. | 09-25-2014 |
20140315994 | METHOD FOR TREATING GASTROINTESTINAL DISORDER - The present invention relates to a method for the long term treatment of gastrointestinal disorders in a human subject, which comprises administering an effective amount of a halogenated prostaglandin compound and/or its tautomer to the subject. The method induces substantially no electrolyte shifting during the term of the treatment. The compound used in the present invention can improve quality of life in the human subjects with gastrointestinal disorders, are similarly effective in treating male and female subjects, and also effective in a human subject aged even 65 years and older. | 10-23-2014 |
20140371309 | OPHTHALMIC SOLUTION - The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient. | 12-18-2014 |